From: Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
Source of the transition probability matrix
Only the clinical trial
Expert opinion + clinical trial
Vague prior + clinical trial
QALY cariprazine
0.7562
0.7540
0.7512
QALY risperidone
0.7302
0.7287
0.7269
QALY difference
0.0260
0.0253
0.0243